A shortage of Epanutin Infatabs 50 mg has been confirmed in Ireland by the HPRA.
Manufacturing delays have been cited as the reason behind the delay and at present, there is no known date for the return of supply.
In the interim and for the duration of this shortage, the unlicensed product Dilantin Infatabs 50 mg will be made available in Ireland. Further details about this product and the caution in use letter which should be supplied with this medication can be found here.
Minister Simon Harris was questioned in the Dáíl by Deputy Pat Buckley and gave the following information to the Dáil:
"The company is changing its manufacturing site and this has resulted in the shortage. The company is taking all possible steps to ensure that normal supply resumes as soon as possible. However, in order to mitigate any impact of the shortage to patients, the company is supplying the product it places on the Australian market under a different brand name — Dilantin Infatabs 50mg.”
We will continue to monitor this situation and provide further updates when they become available. We have reached out to both the HPRA and the supplier of Epanutin seeking further details on this issue.
We would encourage you to please speak to your medical team or epilepsy nurse specialist regarding this shortage should you have any concerns.